A clinical phase I for AlgiPharma’s prospective medicine for Cystic Fibrosis (respiratory diseases), Oligo-G CF-5/20, was approved by the Medicines and Healthcare Product Regulatory Agency, MRHA, and is initiated at SIMBEC (UK) and scheduled to be concluded before the end of the year. Results are set to be reported in the first quarter of 2010.
For more information contact:
Yngvar P. Berg, CEO, +47 90044903; email@example.com
Astrid Hilde Myrset, Clinical Director, +47 93026094; firstname.lastname@example.org